Free Trial

Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Neumora Therapeutics logo
$1.83 +0.05 (+2.81%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$1.82 -0.01 (-0.49%)
As of 10/3/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neumora Therapeutics Stock (NASDAQ:NMRA)

Advanced

Key Stats

Today's Range
$1.77
$1.93
50-Day Range
$1.44
$2.28
52-Week Range
$0.61
$17.19
Volume
713,248 shs
Average Volume
457,610 shs
Market Capitalization
$296.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.14
Consensus Rating
Hold

Company Overview

Neumora Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

NMRA MarketRank™: 

Neumora Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 588th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neumora Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 4 hold ratings, and 3 sell ratings.

  • Upside Potential

    Neumora Therapeutics has a consensus price target of $7.14, representing about 290.3% upside from its current price of $1.83.

  • Amount of Analyst Coverage

    Neumora Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Neumora Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neumora Therapeutics are expected to grow in the coming year, from ($1.61) to ($1.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neumora Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neumora Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neumora Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Neumora Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.84% of the float of Neumora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neumora Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Neumora Therapeutics has recently increased by 22.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neumora Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Neumora Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.84% of the float of Neumora Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Neumora Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Neumora Therapeutics has recently increased by 22.75%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Neumora Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Neumora Therapeutics this week, compared to 8 articles on an average week.
  • MarketBeat Follows

    1 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neumora Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.80% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neumora Therapeutics' insider trading history.
Receive NMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NMRA Stock News Headlines

Neumora Therapeutics to Host Virtual R&D Day on October 27
Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
JP Morgan Downgrades Neumora Therapeutics (NMRA)
See More Headlines

NMRA Stock Analysis - Frequently Asked Questions

Neumora Therapeutics' stock was trading at $10.60 at the beginning of 2025. Since then, NMRA stock has decreased by 82.7% and is now trading at $1.83.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) released its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.05.
Read the conference call transcript
.

Neumora Therapeutics (NMRA) raised $250 million in an initial public offering on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.

Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP).

Company Calendar

Last Earnings
8/06/2025
Today
10/05/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NMRA
CIK
1885522
Fax
N/A
Employees
108
Year Founded
2020

Price Target and Rating

High Price Target
$18.00
Low Price Target
$1.00
Potential Upside/Downside
+290.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$243.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-98.95%
Return on Assets
-87.68%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
10.54
Quick Ratio
10.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.78 per share
Price / Book
1.03

Miscellaneous

Outstanding Shares
161,950,000
Free Float
118,544,000
Market Cap
$296.37 million
Optionable
Optionable
Beta
2.92

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:NMRA) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners